(0.01%) 5 479.00 points
(-0.01%) 38 814 points
(0.05%) 19 932 points
(0.26%) $80.54
(0.97%) $2.82
(0.12%) $2 331.80
(-0.33%) $29.30
(-0.03%) $970.60
(0.04%) $0.932
(-0.09%) $10.64
(0.09%) $0.788
(-1.87%) $86.80
Live Chart Being Loaded With Signals
Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich\'s ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations...
Stats | |
---|---|
Šios dienos apimtis | 61 734 |
Vidutinė apimtis | 133 877 |
Rinkos kapitalizacija | 535.36M |
EPS | $-0.770 ( Q1 | 2024-03-31 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
0 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0650 (0.40%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-11-07 | Omega Fund Vi, L.p. | Buy | 454 545 | Common Stock |
2023-11-07 | Omega Fund Vi, L.p. | Buy | 287 213 | Common Stock |
2023-11-07 | Omega Fund Vi, L.p. | Buy | 1 415 865 | Common Stock |
2023-11-07 | Omega Fund Vi, L.p. | Sell | 2 615 533 | Series B convertible preferred stock |
2023-11-07 | Omega Fund Vi, L.p. | Sell | 14 999 999 | Series A convertible preferred stock |
INSIDER POWER |
---|
-79.48 |
Last 16 transactions |
Buy: 4 724 723 | Sell: 41 348 236 |
Tūris Koreliacija
Lexeo Therapeutics, Inc. Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Lexeo Therapeutics, Inc. Koreliacija - Valiuta/Žaliavos
Lexeo Therapeutics, Inc. Finansinės ataskaitos
Annual | 2022 |
Pajamos: | $654 000 |
Bruto pelnas: | $654 000 (100.00 %) |
EPS: | $-2.40 |
FY | 2022 |
Pajamos: | $654 000 |
Bruto pelnas: | $654 000 (100.00 %) |
EPS: | $-2.40 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Lexeo Therapeutics, Inc.
Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich\'s ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.